Tandem Diabetes Care (TNDM) Company Overview

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2024 results after the financial markets close on Wednesday, February 26, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its fourth quarter and full year 2024 financial and operating results. A live webcast of the call.

TNDM enters a multi-year research collaboration with the UVA Center for Diabetes Technology for the development of AID systems.

Tandem Diabetes' t:slim X2 insulin pump is now compatible with Dexcom G7 CGM in Canada.

New developments and strong growth in international markets are boosting investors' confidence in Tandem Diabetes.

Tandem Diabetes' top and bottom lines outpace estimates in the third quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.

While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Flat revenue growth might be in store for the company in a very crucial market.

By integrating ultra-rapid acting insulin such as Lyumjev, which responds faster than traditional insulin, Tandem Diabetes Care is enhancing the pump's functionality.

Tandem Diabetes is driving transformative innovation to help reduce the burden of diabetes and create new possibilities for people living with the condition.